Literature DB >> 21289518

Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β III-tubulin in thymic epithelial tumors.

Kyoichi Kaira1, Masakuni Serizawa, Yasuhiro Koh, Satoru Miura, Rieko Kaira, Masato Abe, Kazuo Nakagawa, Yasuhisa Ohde, Takehiro Okumura, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi, Haruhiko Kondo, Takashi Nakajima, Masahiro Endo, Nobuyuki Yamamoto.   

Abstract

BACKGROUND: We investigated the clinical significance of excision repair cross-complementation group 1 (ERCC1), breast cancer susceptibility 1 (BRCA1), and class III β-tubulin (TUBB3) expression in thymic epithelial tumors.
METHOD: Fifty-six patients with thymic epithelial tumors were included in this study. Tumors sections were stained by immunohistochemistry for ERCC1, BRCA1, TUBB3, microvessel density, and p53.
RESULTS: ERCC1, BRCA1, and TUBB3 were expressed in 48%, 50%, and 27%, respectively. The expression of ERCC1, BRCA1, and TUBB3 was significantly correlated with the grade of malignancy in thymic epithelial tumors. These biomarkers were closely associated with p53 and microvessel density and were a prognostic marker for predicting poor outcome. We also found that overexpression of ERCC1 and TUBB3 was associated with resistance to platinum- and taxane-based chemotherapy.
CONCLUSION: An expression of ERCC1, BRCA1, and TUBB3 was correlated strongly with each other and was significantly associated with a poor outcome in thymic epithelial tumors. High-ERCC1 and TUBB3 expressions might be associated with resistance to platinum- and taxane-based chemotherapy, respectively.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289518     DOI: 10.1097/JTO.0b013e31820b9b35

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  7 in total

1.  Increased α-tubulin1b expression indicates poor prognosis and resistance to chemotherapy in hepatocellular carcinoma.

Authors:  Cuihua Lu; Jing Zhang; Song He; Chunhua Wan; Aidong Shan; Yingying Wang; Litao Yu; Guoliang Liu; Ken Chen; Jing Shi; Yixin Zhang; Runzhou Ni
Journal:  Dig Dis Sci       Date:  2013-04-27       Impact factor: 3.199

2.  Expression of excision repair cross-complementation group 1 and class III β-tubulin in thymic carcinoma.

Authors:  Katsuhiro Okuda; Risa Oda; Ayumi Suzuki; Tsutomu Tatematsu; Hiroshi Haneda; Satoru Moriyama; Motoki Yano; Ryoichi Nakanishi
Journal:  Oncol Lett       Date:  2017-03-06       Impact factor: 2.967

3.  Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors.

Authors:  Yosuke Miura; Kyoichi Kaira; Reiko Sakurai; Hisao Imai; Yoshio Tomizawa; Noriaki Sunaga; Koichi Minato; Takeshi Hisada; Tetsunari Oyama; Masanobu Yamada
Journal:  Oncol Lett       Date:  2017-06-19       Impact factor: 2.967

4.  The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesions.

Authors:  Rossana Berardi; Gaia Goteri; Silvia Pagliaretta; Vittorio Paolucci; Francesca Morgese; Alessandro Conti; Majed Refai; Cecilia Pompili; Claudia Duranti; Giulia Marcantognini; Agnese Savini; Miriam Caramanti; Silvia Rinaldi; Mariangela Torniai; Matteo Santoni; Antonio Zizzi; Paola Mazzanti; Azzurra Onofri; Giulia Ricci; Marina Scarpelli
Journal:  J Thorac Dis       Date:  2020-12       Impact factor: 2.895

5.  Expression of Class III Beta-Tubulin Is Associated with Invasive Potential and Poor Prognosis in Thyroid Carcinoma.

Authors:  Hee Young Na; Mira Park; Young A Kim; Jae Kyung Won; Young Joo Park; Sun Ah Shin; Sejoon Lee; Sohee Oh; Ji Eun Kim
Journal:  J Clin Med       Date:  2020-11-26       Impact factor: 4.241

6.  Emodin affects ERCC1 expression in breast cancer cells.

Authors:  Jian-min Fu; Jie Zhou; Jian Shi; Jian-sheng Xie; Li Huang; Adrian Y S Yip; Wings T Y Loo; Louis W C Chow; Elizabeth L Y Ng
Journal:  J Transl Med       Date:  2012-09-19       Impact factor: 5.531

7.  Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy.

Authors:  Rossana Berardi; Alessandro Brunelli; Silvia Pagliaretta; Vittorio Paolucci; Alessandro Conti; Gaia Goteri; Majed Refai; Cecilia Pompili; Giulia Marcantognini; Francesca Morgese; Zelmira Ballatore; Agnese Savini; Mariagrazia De Lisa; Miriam Caramanti; Matteo Santoni; Antonio Zizzi; Francesco Piva; Paola Mazzanti; Azzurra Onofri; Armando Sabbatini; Marina Scarpelli; Stefano Cascinu
Journal:  Oncotarget       Date:  2015-08-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.